Cybin to Present at Guggenheim Healthcare Innovation Conference Amid Phase 3 Mental Health Drug Development

Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a Phase 3 clinical stage neuropsychiatry company, announced that Chief Business Officer George Tziras will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference scheduled for November 10-12, 2025, in Boston, Massachusetts. The company's participation comes at a critical juncture as it advances multiple psychiatric drug candidates through clinical development.

The conference appearance holds significance as Cybin continues developing innovative mental healthcare treatments at a time when mental health disorders represent a growing global health crisis. The company's focus on transforming mental healthcare through proprietary drug discovery and delivery technologies addresses the substantial unmet medical needs affecting millions worldwide. Cybin's clinical pipeline includes CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for adjunctive treatment of major depressive disorder. This investigational treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential to demonstrate substantial improvement over existing therapies.

Additionally, the company is developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder. Cybin maintains a research pipeline of investigational compounds focused on 5-HT receptors, targeting various psychiatric conditions. The company's participation in the healthcare innovation conference provides an opportunity to discuss these developments with investors and industry stakeholders. More information about the company's progress is available in their newsroom at https://ibn.fm/CYBN.

Founded in 2019, Cybin operates across multiple countries including Canada, the United States, the United Kingdom and Ireland, positioning itself as a global player in neuropsychiatry drug development. The company's work represents an important advancement in mental health treatment innovation, particularly as traditional antidepressant and anti-anxiety medications often provide incomplete relief for many patients. The full press release detailing the conference participation can be viewed at https://ibn.fm/uqBYE.

This development matters because mental health conditions affect approximately one in four people globally, creating an urgent need for more effective treatments. Cybin's approach using novel psychedelic-inspired compounds could potentially revolutionize treatment paradigms for depression and anxiety disorders. The company's progress through Phase 3 clinical trials represents a significant milestone in the broader acceptance and development of alternative mental health treatments within mainstream medicine. As mental healthcare continues to evolve, companies like Cybin are at the forefront of developing next-generation therapies that may offer improved efficacy and durability compared to existing options.